The Financial Impact of Ustekinumab Biosimilars
The introduction of ustekinumab biosimilars is fundamentally altering the financial landscape of the market. With list prices significantly lower than that of the originator drug, biosimilars are poised to generate substantial cost savings for healthcare systems, payers, and patients. Private-label strategies and aggressive pricing from pharmacy benefit managers (PBMs) are further intensifying this price competition. This shift is not just about lowering drug costs; it is also about making effective biologic therapies more accessible and sustainable for the long term. The financial dynamics of the ustekinumab market serve as a case study for the broader biosimilar industry and its role in drug affordability.
Understand the financial impact of Ustekinumab biosimilars
FAQs:
How much cheaper are ustekinumab biosimilars compared to Stelara? Some ustekinumab biosimilars have launched with discounts as high as 80-90% compared to Stelara's wholesale acquisition cost (WAC).
What role do PBMs play in the ustekinumab market? PBMs are influencing the market by using private-label strategies and mandating or incentivizing the use of lower-cost biosimilars through their formularies.